{
 "name": "安成生技",
 "slug": "tw-6610",
 "aliases": [
  "安成生物科技股份有限公司",
  "TWi Biotech.",
  "6610"
 ],
 "ticker": "6610",
 "industry": "生技醫療業",
 "website": "www.twibiotech.com",
 "summary": "安成生技（6610）是興櫃的生技醫療類股公司，2010 年成立，2016 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "安成生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "TWi Biotech.",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2016-12-27",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2010-07-16",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "吳怡君",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "蔡承恩",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 2235793950,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "www.twibiotech.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：AC-203",
   "value": "單純型遺傳性表皮分解性水皰症（EBS）｜全球第II/III期主要指標未達統計顯著，後續開發策略評估｜全球",
   "unit": "",
   "as_of": "2026-10-18",
   "source": "https://www.twibiotech.com/tw/news/content/ac_203%E6%B2%BB%E7%99%82%E5%96%AE%E7%B4%94%E5%9E%8B%E9%81%BA%E5%82%B3%E6%80%A7%E8%A1%A8%E7%9A%AE%E5%88%86%E8%A7%A3%E6%80%A7%E6%B0%B4%E7%9A%B0%E7%97%87__ebs__%E7%AC%AC%E4%BA%8C_%E4%B8%89%E6%9C%9F%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E4%B8%BB%E8%A6%81%E7%99%82%E6%95%88%E6%8C%87%E6%A8%99%E7%B5%90%E6%9E%9C?category=all&page=1",
   "note": "NCT06073132；全球第II/III期EBShield主要指標未達顯著，並非NDA送件/核准。"
  },
  {
   "claim": "管線：AC-1101（tofacitinib）",
   "value": "圓禿｜已向TFDA提出第IIa期IND申復審查申請｜台灣",
   "unit": "",
   "as_of": "2026-09-02",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E7%94%A8%E6%96%BC%E6%B2%BB%E7%99%82%E5%9C%93%E7%A6%BF%E4%B9%8B%E9%96%8B%E7%99%BC%E4%B8%AD%E6%96%B0%E8%97%A5ac_1101_%E5%90%91%E8%A1%9B%E7%94%9F%E7%A6%8F_%E5%88%A9%E9%83%A8%E9%A3%9F%E5%93%81%E8%97%A5%E7%89%A9%E7%AE%A1%E7%90%86%E7%BD%B2_tfda_%E6%8F%90%E5%87%BA%E7%AC%AC2a%E6%9C%9F%E4%BA%BA%E9%AB%94%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97_ind_%E4%B9%8B_%E7%94%B3%E5%BE%A9%E5%AF%A9%E6%9F%A5%E7%94%B3%E8%AB%8B?category=all&page=1",
   "note": "申復提出日；不是已核准啟動第IIa期。"
  },
  {
   "claim": "管線：AC-1101（tofacitinib）",
   "value": "環狀肉芽腫｜第I期已完成（歷史試驗）｜美國",
   "unit": "",
   "as_of": "2024-10-15",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT05580042",
   "note": "NCT05580042；ClinicalTrials.gov最後公開更新 2024-10-15；登錄狀態 COMPLETED。"
  },
  {
   "claim": "管線：NORA520",
   "value": "產後憂鬱症｜第II期已完成（試驗完成不等於療效達標）｜美國",
   "unit": "",
   "as_of": "2026-07-31",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06285916",
   "note": "NCT06285916；ClinicalTrials.gov最後公開更新 2026-07-31；登錄狀態 COMPLETED。"
  },
  {
   "claim": "催化劑：AC-203",
   "value": "與FDA及EMA進行法規諮詢會議｜2027Q1（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-19",
   "source": "https://www.twibiotech.com/tw/news/content/%E5%AE%89%E6%88%90%E7%94%9F%E6%8A%80%E8%AA%AA%E6%98%8E_ac_203_%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E7%B5%90%E6%9E%9C_%E9%83%A8%E5%88%86%E7%99%82%E6%95%88%E6%8C%87%E6%A8%99%E5%91%88%E7%8F%BE%E6%AD%A3%E5%90%91%E8%A8%8A%E8%99%9F_%E6%8C%81%E7%BA%8C%E8%88%87_fda_ema_%E6%BA%9D%E9%80%9A%E8%97%A5%E8%AD%89%E7%94%B3%E8%AB%8B%E5%8F%AF%E8%83%BD%E6%80%A7?category=all&page=1",
   "note": "公司於主要指標未達顯著後更新的開發規劃；不是主管機關已排定的確定會議日期。"
  },
  {
   "claim": "催化劑：AC-203",
   "value": "若取得法規單位正向回應，預計提出藥證申請｜2027下半年（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-10-19",
   "source": "https://www.twibiotech.com/tw/news/content/%E5%AE%89%E6%88%90%E7%94%9F%E6%8A%80%E8%AA%AA%E6%98%8E_ac_203_%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E7%B5%90%E6%9E%9C_%E9%83%A8%E5%88%86%E7%99%82%E6%95%88%E6%8C%87%E6%A8%99%E5%91%88%E7%8F%BE%E6%AD%A3%E5%90%91%E8%A8%8A%E8%99%9F_%E6%8C%81%E7%BA%8C%E8%88%87_fda_ema_%E6%BA%9D%E9%80%9A%E8%97%A5%E8%AD%89%E7%94%B3%E8%AB%8B%E5%8F%AF%E8%83%BD%E6%80%A7?category=all&page=1",
   "note": "附條件公司規劃；沒有將2028年取證目標塞入截至2028-04-22的窗口。"
  },
  {
   "claim": "授權合作：AC-203",
   "value": "Minophagen Pharmaceutical Co., Ltd.｜日本｜2020-12-01",
   "unit": "",
   "as_of": "2020-12-01",
   "source": "https://www.twibiotech.com/tw/news/content/%E5%AE%89%E6%88%90%E7%94%9F%E6%8A%80%E9%A0%86%E5%88%A9%E5%AE%8C%E6%88%90%E8%88%87%E6%97%A5%E6%9C%ACminophagen%E7%B0%BD%E8%A8%82ac_203%E7%9A%AE%E8%86%9A%E5%A4%96%E7%94%A8%E5%8A%91%E5%9E%8B%E6%8E%88%E6%AC%8A%E5%8F%8A%E9%96%8B%E7%99%BC%E5%90%88%E7%B4%84?category=all&page=7",
   "note": "歷史簽約；2024年度年報重要契約仍列日本研發銷售權，年報不是新的簽字日期證明。"
  },
  {
   "claim": "簽約金：AC-203（Minophagen）",
   "value": 100000000,
   "unit": "日圓",
   "as_of": "2021-01-26",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%BE%9D%E7%B4%84%E5%B7%B2%E5%85%A8%E9%A1%8D%E6%94%B6%E8%B6%B3%E6%97%A5%E6%9C%ACminophagen_pharmaceutical_co__ltd%E5%8F%8A%E9%A6%99%E6%B8%AF%E7%B6%AD%E5%81%A5%E9%86%AB%E8%97%A5%E9%9B%86%E5%9C%98%E6%89%80%E6%94%AF%E4%BB%98ac_203%E6%8E%88%E6%AC%8A%E7%B0%BD%E7%B4%84%E9%87%91%E5%88%86%E5%88%A5%E7%82%BA%E6%97%A5%E5%B9%A31%E5%84%84%E5%85%83%E5%8F%8A%E7%BE%8E%E9%87%91150%E8%90%AC%E5%85%83?category=all&page=7",
   "note": "日本授權；稅前簽約金。不是里程碑總額。"
  },
  {
   "claim": "已收金額（公告日為準）：AC-203（Minophagen）",
   "value": 95000000,
   "unit": "日圓",
   "as_of": "2021-01-26",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%BE%9D%E7%B4%84%E5%B7%B2%E5%85%A8%E9%A1%8D%E6%94%B6%E8%B6%B3%E6%97%A5%E6%9C%ACminophagen_pharmaceutical_co__ltd%E5%8F%8A%E9%A6%99%E6%B8%AF%E7%B6%AD%E5%81%A5%E9%86%AB%E8%97%A5%E9%9B%86%E5%9C%98%E6%89%80%E6%94%AF%E4%BB%98ac_203%E6%8E%88%E6%AC%8A%E7%B0%BD%E7%B4%84%E9%87%91%E5%88%86%E5%88%A5%E7%82%BA%E6%97%A5%E5%B9%A31%E5%84%84%E5%85%83%E5%8F%8A%E7%BE%8E%E9%87%91150%E8%90%AC%E5%85%83?category=all&page=7",
   "note": "公告所列稅後簽約金；稅前1億日圓，僅截至2021-01-26，不代表2026累計收款。"
  },
  {
   "claim": "簽約金：AC-203（香港維健）",
   "value": 1500000,
   "unit": "美元",
   "as_of": "2021-01-26",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%BE%9D%E7%B4%84%E5%B7%B2%E5%85%A8%E9%A1%8D%E6%94%B6%E8%B6%B3%E6%97%A5%E6%9C%ACminophagen_pharmaceutical_co__ltd%E5%8F%8A%E9%A6%99%E6%B8%AF%E7%B6%AD%E5%81%A5%E9%86%AB%E8%97%A5%E9%9B%86%E5%9C%98%E6%89%80%E6%94%AF%E4%BB%98ac_203%E6%8E%88%E6%AC%8A%E7%B0%BD%E7%B4%84%E9%87%91%E5%88%86%E5%88%A5%E7%82%BA%E6%97%A5%E5%B9%A31%E5%84%84%E5%85%83%E5%8F%8A%E7%BE%8E%E9%87%91150%E8%90%AC%E5%85%83?category=all&page=7",
   "note": "同一2021-01-26收款公告明載香港維健醫藥集團簽署AC-203皮膚外用劑型授權及開發合約、簽約金美金150萬元已收迄；本來源未列授權地域、精確簽約日及交易總額，不從其他交易推定。簽約金與已收金額為同一筆款項，不相加。"
  },
  {
   "claim": "已收金額（公告日為準）：AC-203（香港維健）",
   "value": 1500000,
   "unit": "美元",
   "as_of": "2021-01-26",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%BE%9D%E7%B4%84%E5%B7%B2%E5%85%A8%E9%A1%8D%E6%94%B6%E8%B6%B3%E6%97%A5%E6%9C%ACminophagen_pharmaceutical_co__ltd%E5%8F%8A%E9%A6%99%E6%B8%AF%E7%B6%AD%E5%81%A5%E9%86%AB%E8%97%A5%E9%9B%86%E5%9C%98%E6%89%80%E6%94%AF%E4%BB%98ac_203%E6%8E%88%E6%AC%8A%E7%B0%BD%E7%B4%84%E9%87%91%E5%88%86%E5%88%A5%E7%82%BA%E6%97%A5%E5%B9%A31%E5%84%84%E5%85%83%E5%8F%8A%E7%BE%8E%E9%87%91150%E8%90%AC%E5%85%83?category=all&page=7",
   "note": "僅截至2021-01-26公告已收迄簽約金；不是2026累計收款。"
  },
  {
   "claim": "授權合作：AC-1101",
   "value": "Inmagene Biopharmaceuticals｜中國、香港、澳門、南韓（附條件）；全球不含台灣（選擇權）｜2021-06-28",
   "unit": "",
   "as_of": "2021-06-28",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%88%87inmagene_biopharmaceuticals%E6%AD%A3%E5%BC%8F%E7%B0%BD%E8%A8%82%E5%85%B1%E5%90%8C%E9%96%8B%E7%99%BC_ac_1101%E6%96%B0%E8%97%A5%E6%9A%A8%E6%8E%88%E6%AC%8A%E5%90%88%E7%B4%84?category=all&page=7",
   "note": "歷史簽約及附條件權利；不表示選擇權已行使。2026現行合約存續未能確認。"
  },
  {
   "claim": "簽約金：AC-1101（Inmagene，上限）",
   "value": 12000000,
   "unit": "美元",
   "as_of": "2021-06-28",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%88%87inmagene_biopharmaceuticals%E6%AD%A3%E5%BC%8F%E7%B0%BD%E8%A8%82%E5%85%B1%E5%90%8C%E9%96%8B%E7%99%BC_ac_1101%E6%96%B0%E8%97%A5%E6%9A%A8%E6%8E%88%E6%AC%8A%E5%90%88%E7%B4%84?category=all&page=7",
   "note": "最高可達的簽約金；不是已收款。歷史公告，現行存續未能確認。"
  },
  {
   "claim": "里程碑金上限：AC-1101（Inmagene，研發）",
   "value": 114000000,
   "unit": "美元",
   "as_of": "2021-06-28",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%88%87inmagene_biopharmaceuticals%E6%AD%A3%E5%BC%8F%E7%B0%BD%E8%A8%82%E5%85%B1%E5%90%8C%E9%96%8B%E7%99%BC_ac_1101%E6%96%B0%E8%97%A5%E6%9A%A8%E6%8E%88%E6%AC%8A%E5%90%88%E7%B4%84?category=all&page=7",
   "note": "依里程碑達成條件支付，與銷售里程金分列，未加總推算。歷史公告。"
  },
  {
   "claim": "里程碑金上限：AC-1101（Inmagene，銷售）",
   "value": 295000000,
   "unit": "美元",
   "as_of": "2021-06-28",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%88%87inmagene_biopharmaceuticals%E6%AD%A3%E5%BC%8F%E7%B0%BD%E8%A8%82%E5%85%B1%E5%90%8C%E9%96%8B%E7%99%BC_ac_1101%E6%96%B0%E8%97%A5%E6%9A%A8%E6%8E%88%E6%AC%8A%E5%90%88%E7%B4%84?category=all&page=7",
   "note": "依銷售里程碑達成支付；不是已收款。歷史公告。"
  },
  {
   "claim": "權利金比率：AC-1101（Inmagene）",
   "value": "個位數至雙位數",
   "unit": "%",
   "as_of": "2021-06-28",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%88%87inmagene_biopharmaceuticals%E6%AD%A3%E5%BC%8F%E7%B0%BD%E8%A8%82%E5%85%B1%E5%90%8C%E9%96%8B%E7%99%BC_ac_1101%E6%96%B0%E8%97%A5%E6%9A%A8%E6%8E%88%E6%AC%8A%E5%90%88%E7%B4%84?category=all&page=7",
   "note": "以產品上市後淨銷售額按級距計；官方未公開精確百分比，未轉成自行推估區間。歷史公告。"
  },
  {
   "claim": "授權合作：AC-203（香港維健；收款公告）",
   "value": "香港維健醫藥集團｜授權地區查無｜2021-01-26",
   "unit": "",
   "as_of": "2021-01-26",
   "source": "https://www.twibiotech.com/tw/news/content/%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%BE%9D%E7%B4%84%E5%B7%B2%E5%85%A8%E9%A1%8D%E6%94%B6%E8%B6%B3%E6%97%A5%E6%9C%ACminophagen_pharmaceutical_co__ltd%E5%8F%8A%E9%A6%99%E6%B8%AF%E7%B6%AD%E5%81%A5%E9%86%AB%E8%97%A5%E9%9B%86%E5%9C%98%E6%89%80%E6%94%AF%E4%BB%98ac_203%E6%8E%88%E6%AC%8A%E7%B0%BD%E7%B4%84%E9%87%91%E5%88%86%E5%88%A5%E7%82%BA%E6%97%A5%E5%B9%A31%E5%84%84%E5%85%83%E5%8F%8A%E7%BE%8E%E9%87%91150%E8%90%AC%E5%85%83?category=all&page=7",
   "note": "末段為收款公告日，非精確簽約日；本來源只明載已簽AC-203皮膚外用劑型授權及開發合約，精確簽約日及地域查無，未拿日本Minophagen交易地域套用。配對香港維健150萬美元簽約金及已收金額，二者是同一款項，不相加。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6610.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}